2014 Eberhard F. Mammen Award Announcements: Part I—Most Popular Articles

Welcome to another Eberhard F. Mammen award announcement. As noted previously,[1] [2] [3] Thieme, the publisher of Seminars in Thrombosis & Hemostasis, has created the Eberhard F. Mammen Excellence in Thrombosis and Hemostasis Awards in the honor of Dr. Eberhard F. Mammen ([Fig. 1]), and in recognition of his contribution to this field and to the journal that he both founded and steered for over three decades. These awards began in 2009 under two categories:

Fig. 1 Eberhard F. Mammen (1930–2008).

• Most Popular Article Awards: Awarded to the authors of the most popular articles published in Seminars in Thrombosis & Hemostasis. The awards are determined by the Editor in Chief on the basis of user statistics from Thieme e-Journals from the preceding 2 years. The awards comprise two major cash prizes of US$1,000 plus “open access” status for these articles thereafter.

• Young Investigator Awards: Best presentation or meeting abstract by a young investigator—as presented or delivered to an international or large regional meeting on a topic related to the fields of thrombosis and hemostasis and whose subject matter is determined to be in the spirit of Dr. Mammen. Up to six cash prizes of US$1,000 are awarded in any year. Awardees are expected to prepare a review or an article related to the topic of their presentation for publication in Seminars in Thrombosis & Hemostasis.

Further details of the awards and the award winners are posted online (<http://www.thieme.com/sth>), and previous award winner announcements are also available in print.[4] [5] [6] [7] [8] [9]

It is, therefore, with great pleasure that we would like to announce the latest winners of the 2014 Eberhard F. Mammen awards for the most popular articles from Seminars in Thrombosis & Hemostasis for the period 2012 to 2013 inclusive. We will be announcing the young investigator awards related to meetings held in the recent past on a later date.

• References

• 1 Favaloro EJ. Editorial. Welcome to a special issue of Seminars in Thrombosis and Hemostasis—the closing issue for 2008. Semin Thromb Hemost 2008; 34: 693-696
• 2 Favaloro EJ. A tribute to Eberhard F. Mammen, M.D. (1930–2008). Semin Thromb Hemost 2008; 34 (8) 703-707
• 3 Favaloro EJ. Editorial. Welcome to the first issue of Seminars in Thrombosis and Hemostasis for 2009. Semin Thromb Hemost 2009; 35: 1-2
• 4 Favaloro EJ. Editorial. Winners of the inaugural Eberhard F. Mammen Award for most popular article. Semin Thromb Hemost 2009; 35: 587-590
• 5 Favaloro EJ. Editorial. 2009 Eberhard F. Mammen Young Investigator Award winners. Semin Thromb Hemost 2010; 36: 469-470
• 6 Favaloro EJ. Winners of the 2010 Eberhard F. Mammen award for most popular article during 2008–2009. Semin Thromb Hemost 2010; 36 (7) 685-692
• 7 Favaloro EJ. 2011 Eberhard F. Mammen award announcements. Semin Thromb Hemost 2011; 37 (5) 431-439
• 8 Favaloro EJ. 2012 Eberhard F. Mammen award announcements. Semin Thromb Hemost 2012; 38: 425-432
• 9 Favaloro EJ. Eberhard F. Mammen award announcements. Semin Thromb Hemost 2013; 39: 567-574
• 10 Chapman K, Seldon M, Richards R. Thrombotic microangiopathies, thrombotic thrombocytopenic purpura, and ADAMTS-13. Semin Thromb Hemost 2012; 38 (1) 47-54
• 11 Kenet G, Aronis S, Berkun Y , et al. Impact of persistent antiphospholipid antibodies on risk of incident symptomatic thromboembolism in children: a systematic review and meta-analysis. Semin Thromb Hemost 2011; 37 (7) 802-809
• 12 Aatonen M, Grönholm M, Siljander PR. Platelet-derived microvesicles: multitalented participants in intercellular communication. Semin Thromb Hemost 2012; 38 (1) 102-113
• 13 Kulkarni R, Soucie JM. Pediatric hemophilia: a review. Semin Thromb Hemost 2011; 37 (7) 737-744
• 14 Stasi R. Immune thrombocytopenia: pathophysiologic and clinical update. Semin Thromb Hemost 2012; 38 (5) 454-462
• 15 Lyle CA, Bernard TJ, Goldenberg NA. Childhood arterial ischemic stroke: a review of etiologies, antithrombotic treatments, prognostic factors, and priorities for future research. Semin Thromb Hemost 2011; 37 (7) 786-793
• 16 Schulman S, Majeed A. The oral thrombin inhibitor dabigatran: strengths and weaknesses. Semin Thromb Hemost 2012; 38 (1) 7-15
• 17 Kadir RA, McLintock C. Thrombocytopenia and disorders of platelet function in pregnancy. Semin Thromb Hemost 2011; 37 (6) 640-652
• 18 Tan CW, Ward CM, Morel-Kopp MC. Evaluating heparin-induced thrombocytopenia: the old and the new. Semin Thromb Hemost 2012; 38 (2) 135-143
• 19 Breakey VR, Blanchette VS. Childhood immune thrombocytopenia: a changing therapeutic landscape. Semin Thromb Hemost 2011; 37 (7) 745-755
• 20 Lacroix R, Robert S, Poncelet P, Dignat-George F. Overcoming limitations of microparticle measurement by flow cytometry. Semin Thromb Hemost 2010; 36 (8) 807-818
• 21 Jayandharan GR, Srivastava A, Srivastava A. Role of molecular genetics in hemophilia: from diagnosis to therapy. Semin Thromb Hemost 2012; 38 (1) 64-78
• 22 Coppola A, Favaloro EJ, Tufano A, Di Minno MN, Cerbone AM, Franchini M. Acquired inhibitors of coagulation factors: Part I—acquired hemophilia A. Semin Thromb Hemost 2012; 38 (5) 433-446
• 23 Bates SM. D-dimer assays in diagnosis and management of thrombotic and bleeding disorders. Semin Thromb Hemost 2012; 38 (7) 673-682
• 24 Pels SG. Current therapies in primary immune thrombocytopenia. Semin Thromb Hemost 2011; 37 (6) 621-630
• 25 Prechel M, Walenga JM. Heparin-induced thrombocytopenia: an update. Semin Thromb Hemost 2012; 38 (5) 483-496
• 26 Szántó T, Joutsi-Korhonen L, Deckmyn H, Lassila R. New insights into von Willebrand disease and platelet function. Semin Thromb Hemost 2012; 38 (1) 55-63
• 27 Willis R, Harris EN, Pierangeli SS. Pathogenesis of the antiphospholipid syndrome. Semin Thromb Hemost 2012; 38 (4) 305-321
• 28 Harenberg J, Giese C, Marx S, Krämer R. Determination of dabigatran in human plasma samples. Semin Thromb Hemost 2012; 38 (1) 16-22
• 29 Harenberg J, Erdle S, Marx S, Krämer R. Determination of rivaroxaban in human plasma samples. Semin Thromb Hemost 2012; 38 (2) 178-184
• 30 Favaloro EJ, Wong RC. The antiphospholipid syndrome: diagnosis, pathogenesis, laboratory testing, and management. Semin Thromb Hemost 2012; 38 (4) 299-304
• 31 Coppola A, Tagliaferri A, Di Capua M, Franchini M. Prophylaxis in children with hemophilia: evidence-based achievements, old and new challenges. Semin Thromb Hemost 2012; 38 (1) 79-94
• 32 Linden MD, Tran H, Woods R, Tonkin A. High platelet reactivity and antiplatelet therapy resistance. Semin Thromb Hemost 2012; 38 (2) 200-212
• 33 Coppola A, Tufano A, Di Capua M, Franchini M. Bleeding and thrombosis in multiple myeloma and related plasma cell disorders. Semin Thromb Hemost 2011; 37 (8) 929-945
• 34 Montagnana M, Favaloro EJ, Lippi G. Coffee intake and cardiovascular disease: virtue does not take center stage. Semin Thromb Hemost 2012; 38 (2) 164-177
• 35 Tsai HM. Autoimmune thrombotic microangiopathy: advances in pathogenesis, diagnosis, and management. Semin Thromb Hemost 2012; 38 (5) 469-482
• 36 Scharf RE. Drugs that affect platelet function. Semin Thromb Hemost 2012; 38 (8) 865-883
• 37 Galli M. Interpretation and recommended testing for antiphospholipid antibodies. Semin Thromb Hemost 2012; 38 (4) 348-352
• 38 Zoellner H. Dental infection and vascular disease. Semin Thromb Hemost 2011; 37 (3) 181-192
• 39 Lippi G, Favaloro EJ, Cervellin G. Prevention of venous thromboembolism: focus on mechanical prophylaxis. Semin Thromb Hemost 2011; 37 (3) 237-251
• 40 Franchini M, Lippi G, Favaloro EJ. Acquired inhibitors of coagulation factors: part II. Semin Thromb Hemost 2012; 38 (5) 447-453
• 41 Rojas-Hernandez CM, Garcia DA. The novel oral anticoagulants. Semin Thromb Hemost 2013; 39 (2) 117-126
• 42 Adams M. Tissue factor pathway inhibitor: new insights into an old inhibitor. Semin Thromb Hemost 2012; 38 (2) 129-134
• 43 Les I, Ruiz-Irastorza G, Khamashta MA. Intensity and duration of anticoagulation therapy in antiphospholipid syndrome. Semin Thromb Hemost 2012; 38 (4) 339-347
• 44 Köse O, Zimmerhackl LB, Jungraithmayr T, Mache C, Nürnberger J. New treatment options for atypical hemolytic uremic syndrome with the complement inhibitor eculizumab. Semin Thromb Hemost 2010; 36 (6) 669-672
• 45 Cervera R, Espinosa G. Update on the catastrophic antiphospholipid syndrome and the “CAPS Registry”. Semin Thromb Hemost 2012; 38 (4) 333-338
• 46 De Franceschi L, Cappellini MD, Olivieri O. Thrombosis and sickle cell disease. Semin Thromb Hemost 2011; 37 (3) 226-236
• 47 Thom KE, Hanslik A, Male C. Anticoagulation in children undergoing cardiac surgery. Semin Thromb Hemost 2011; 37 (7) 826-833
• 48 Bitzan M, Schaefer F, Reymond D. Treatment of typical (enteropathic) hemolytic uremic syndrome. Semin Thromb Hemost 2010; 36 (6) 594-610
• 49 Flaumenhaft R, Mairuhu AT, Italiano JE. Platelet- and megakaryocyte-derived microparticles. Semin Thromb Hemost 2010; 36 (8) 881-887
• 50 Ranucci M, Baryshnikova E, Colella D. Monitoring prohemostatic treatment in bleeding patients. Semin Thromb Hemost 2012; 38 (3) 282-291
• 51 Favaloro EJ. Clinical utility of the PFA-100. Semin Thromb Hemost 2008; 34 (8) 709-733
• 52 Cuker A. Current and emerging therapeutics for heparin-induced thrombocytopenia. Semin Thromb Hemost 2012; 38 (1) 31-37
• 53 Toriello HV. Thrombocytopenia-absent radius syndrome. Semin Thromb Hemost 2011; 37 (6) 707-712
• 54 Schroeder V, Kohler HP. Factor XIII deficiency: an update. Semin Thromb Hemost 2013; 39 (6) 632-641
• 55 Kuperman AA, Kenet G, Papadakis E, Brenner B. Intraventricular hemorrhage in preterm infants: coagulation perspectives. Semin Thromb Hemost 2011; 37 (7) 730-736
• 56 Heleen van Ommen C, Middeldorp S. Thrombophilia in childhood: to test or not to test. Semin Thromb Hemost 2011; 37 (7) 794-801
• 57 Darvish-Kazem S, Douketis JD. Perioperative management of patients having noncardiac surgery who are receiving anticoagulant or antiplatelet therapy: an evidence-based but practical approach. Semin Thromb Hemost 2012; 38 (7) 652-660
• 58 Franchini M, Vescovi PP, Garofano M, Veneri D. Helicobacter pylori-associated idiopathic thrombocytopenic purpura: a narrative review. Semin Thromb Hemost 2012; 38 (5) 463-468
• 59 Hellgren M. Hemostasis during normal pregnancy and puerperium. Semin Thromb Hemost 2003; 29 (2) 125-130
• 60 Salmela B, Joutsi-Korhonen L, Armstrong E, Lassila R. Active online assessment of patients using new oral anticoagulants: bleeding risk, compliance, and coagulation analysis. Semin Thromb Hemost 2012; 38 (1) 23-30
• 61 Lippi G, Franchini M, Favaloro EJ, Targher G. Moderate red wine consumption and cardiovascular disease risk: beyond the “French paradox”. Semin Thromb Hemost 2010; 36 (1) 59-70
• 62 Rak J. Microparticles in cancer. Semin Thromb Hemost 2010; 36 (8) 888-906
• 63 Jurk K, Kehrel BE. Platelets: physiology and biochemistry. Semin Thromb Hemost 2005; 31 (4) 381-392
• 64 Tufano A, Guida A, Di Minno MN, Prisco D, Cerbone AM, Di Minno G. Prevention of venous thromboembolism in medical patients with thrombocytopenia or with platelet dysfunction: a review of the literature. Semin Thromb Hemost 2011; 37 (3) 267-274
• 65 Mariani G, Bernardi F. Factor VII deficiency. Semin Thromb Hemost 2009; 35 (4) 400-406
• 66 Fava C, Montagnana M, Favaloro EJ, Guidi GC, Lippi G. Obstructive sleep apnea syndrome and cardiovascular diseases. Semin Thromb Hemost 2011; 37 (3) 280-297